Industries — page 10
Paychex Raises PEO Growth Outlook After Advisory Mix Shift
PEO and Insurance Solutions revenue rose 12% to $367.6 million as Management Solutions growth cooled to 4%.
General Mills Restores Organic Sales After a Third-Quarter Drop
Organic net sales were essentially flat in the fiscal 2027 first quarter, reversing a 3% organic decline, as reported sales fell 3% to $4.4 billion on the U.S. yogurt sale.
Cintas Raises Fiscal 2027 Outlook After Record Margin
Organic revenue growth reached 8.9% and gross margin hit a record 51.5% of sales in the quarter ended Aug. 31, 2026.
Sprinklr Profit Flips as Asana, Planet Labs Stay Loss-Making
Sprinklr posted GAAP operating and net income in the three months ended April 30, 2026, while Asana and Planet Labs still reported net losses and large accumulated deficits.
Bio-Techne Shareholders Approve Merck KGaA's $11.3 Billion Cash Bid
The life-science tools maker cleared the merger vote as remaining regulatory approvals still stand between the parties and a late-2026 or early-2027 close.
Aermont Completes $1.03 Billion Cash Purchase of Park Holidays
Sun Communities closed the sale of its UK holiday-park business, leaving it a pure-play North American MH and RV owner and operator.
Royal Caribbean to Form $3 Billion Sandals Joint Venture
The cruise operator said the partnership expands it into an adjacent vacation category and accelerates growth of the all-inclusive brands.
Ondas to Buy Three Defense Firms in $56 Million Mixed Deal
The autonomous-systems company said the three purchases will add technologies for autonomous platforms in contested environments.
ONE Nuclear Energy to Go Public via Hennessy VII Combination
The SPAC deal would list the gas-and-SMR developer on Nasdaq as ONEN after a first-half 2026 close.
FMC to Buy Tessenderlo Group in $403 Million Cash Deal
The agricultural sciences company will pay $13.30 a share after a minority stake from Tessenderlo earlier this year.
Accelerant Go-Shop Ends With No Rival Bids
The specialty-insurance platform's 40-day shop produced no alternative offers as the Thoma Bravo take-private remains slated for the first half of 2027.
Apogee Enterprises Completes GroGlass Acquisition
The building-products company closed its purchase of the Riga-based coatings maker to add anti-reflective technology to Performance Surfaces.
Worthington Organic Growth Rebounds After a Slow Close
Organic sales growth accelerated to 7% in the fiscal 2027 first quarter as net sales reached $343.9 million.
Thor Withholds Fiscal 2027 Guidance After Profit Collapse
Fourth-quarter net income attributable to THOR was $40.8 million, or $0.78 a share, as the company deferred fiscal 2027 guidance pending Hershey and Elkhart industry events.
KB Home Backlog Rises After Four-Year Stagnation
The homebuilder posted $1.30 billion of third-quarter revenue and $1.05 a share as deliveries, price and margins recovered sequentially.
AutoZone Reverses Gross-Margin Decline on Tariff Refunds
Fourth-quarter net sales were $6.6 billion, up 5.6%, as gross profit as a percentage of sales reached 53.3%.
Talos Energy Closes $420 Million Gulf of America Asset Purchase
The offshore E&P said the Shell deepwater closing advances its plan to build a long-lived, scaled portfolio.
Progress Software to Buy Domo Platform in $400 Million Cash Deal
The AI infrastructure software company will fold Domo’s cloud-native data platform into its existing offerings and keep the seller as a listed shell with net cash and NOLs.
Ligand to Buy Santen's Ryjunea for $23 Million
The biopharma royalty aggregator is adding the first approved pharmacological treatment for slowing pediatric myopia in the EU and UK to its expanding royalty book.
Cognex to Buy RealSense in $500 Million Cash Deal
The machine-vision company said the purchase is a move into robotic perception as it diversifies its growth engine.
Viking’s GLP-1/GIP agonist advances through Phase 3 development
VK2735’s pivotal injection trials are fully enrolled, while early maintenance findings explore less frequent dosing and an oral Phase 3 start remains planned.
AbbVie’s Rinvoq offers oral treatment for a defined colitis population
The JAK inhibitor’s US label specifies prior TNF-blocker failure or intolerance, and boxed warnings remain central to its use.
Abivax, Merck and Teva–Sanofi pursue the next wave of colitis therapies
Seven selected compounds place investigational programs alongside approved treatments, with trial design and patient setting shaping every comparison.
Merck’s tulisokibart meets a Phase 3 ulcerative-colitis endpoint
The sponsor’s induction readout advances the TL1A program, with detailed results and separate maintenance evidence still important.
Lilly’s Zepbound sets an approved benchmark for dual-agonist obesity drugs
Tirzepatide’s weight-management history helps frame newer candidates, though shared mechanisms do not establish equal efficacy or safety.
Novo Nordisk’s Wegovy provides an established obesity benchmark
Semaglutide’s original weight-management approval and STEP 1 evidence offer a reference point for newer development programs.
AbbVie’s Skyrizi extends its IL-23 role into ulcerative colitis
The approved indication rests on distinct induction and maintenance studies, with longer follow-up continuing.
Lilly’s triple agonist retatrutide heads toward a planned US filing
Phase 3 readouts support a submission target for early 2027, while regulatory review and longer-term questions remain ahead.
Roche and Zealand advance petrelintide’s amylin approach to obesity
Phase 2 findings and a planned combination study build the evidence for an alternative to incretin-only treatment.
Roche and Zealand plan a two-mechanism obesity combination trial
The Phase 2 design pairs petrelintide with enicepatide and compares the combination with its components and placebo.
Lilly’s Foundayo brings oral GLP-1 treatment into the obesity market
Orforglipron received FDA approval in April 2026, adding an oral option alongside injectable medicines.
Lilly and Novo set the backdrop for a changing obesity pipeline
Nine selected compounds span approved treatments, new mechanisms and dosing schedules; unlike trials cannot establish a simple efficacy ranking.
Abivax’s obefazimod nears a planned US filing after Phase 3 readouts
July financing supports the developer’s next steps, but its year-end application target and cash-runway forecast remain plans.
Lilly’s Omvoh follows induction with maintenance in ulcerative colitis
The approved IL-23 antibody starts with infusions and moves to injections, with maintenance evidence drawn from patients who first responded.
Amgen tests monthly obesity treatment with MariTide in Phase 3
The investigational therapy combines GLP-1 activation with GIP blockade; durability and tolerability remain central questions.
Pfizer’s Velsipity brings an oral option to ulcerative colitis
Etrasimod’s approval rests on placebo-controlled evidence, including a year-long study whose design differs from responder-only maintenance trials.
Roche’s enicepatide adds diabetes results as Phase 3 trials recruit
A 48-week Phase 2 readout broadens the obesity program’s evidence, while longer pivotal trials and a combination study address separate questions.
Teva and Sanofi take duvakitug into Phase 3 for ulcerative colitis
The TL1A antibody moves beyond responder-selected Phase 2 findings, backed by shared development costs and commercial rights.
Pfizer’s oral GLP-1 program ended with danuglipron’s discontinuation
A potential liver-injury case preceded the April 2025 decision; completed trial records do not signal an active program.
The Uneven Conversion of Earnings Into Cash
Acquired activity and lower capital spending explain part of a dramatic cash-flow improvement, while peer comparisons show why its recurring organic component remains unquantified.
AnaptysBio Records $177 Million Tax-Driven Profit
Jemperli global net sales reached $331 million in the three months ended June 30, 2026, as AZUR-1 data moved the FDA clock to February 2027.
Woodward to Move Santa Clarita Aerospace Production to Spartanburg
The energy-controls maker will shift military flight-control actuation to South Carolina and sell a smaller group of legacy products as it refines its manufacturing footprint.
Construction Partners Adds Roads, Inc. of NWF
The Florida Panhandle deal folds the contractor into C.W. Roberts to deepen CPI’s public and private infrastructure coverage in the region.
PTC Completes ST-920 Fabry Gene Therapy Purchase
The rare-disease company closed a competitive bankruptcy auction for a BLA-stage AAV program it plans to file in the fourth quarter.
Investor Group to Take Priority Technology Private in $1.6 Billion Cash Deal
Chairman Thomas Priore’s group will buy remaining Priority shares at $8.05, a 65% premium to the pre-proposal close, with Searchlight equity and a first-half 2027 close.
DICK’S Completes $2.5 Billion Foot Locker Acquisition
The sporting-goods retailer closed the mixed cash-and-stock merger on Sept. 8, 2025, folding Foot Locker’s global store base into a standalone unit.
FDA Approves Scholar Rock's ISEMBYLD
Scholar Rock Holding (SRRK) won approval for ISEMBYLD under BLA 761463, with the agency's status date of September 11, 2026.
Leadership Turnover Flags Operational Risk
Four U.S. companies are treating executive and board transitions as a live operational and financial risk, from interim co-CEOs at lululemon to severance at Lands' End.
Catastrophe Loss Relief Drives Reinsurance Pricing Softening
RenaissanceRe's property book swung from a 148.7% combined ratio to 34.1% in a single year, and the relief is already showing up as give-back in reinsurance pricing.
H.I.G. Capital to Buy MISTRAS in $866 Million Cash Deal
The industrial asset-integrity firm will be taken private at $20.35 a share after a 40-day go-shop, with closing expected in late 2026 or early 2027.